HUP0201284A2 - Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient - Google Patents
Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredientInfo
- Publication number
- HUP0201284A2 HUP0201284A2 HU0201284A HUP0201284A HUP0201284A2 HU P0201284 A2 HUP0201284 A2 HU P0201284A2 HU 0201284 A HU0201284 A HU 0201284A HU P0201284 A HUP0201284 A HU P0201284A HU P0201284 A2 HUP0201284 A2 HU P0201284A2
- Authority
- HU
- Hungary
- Prior art keywords
- active ingredient
- quinazolindione
- preventive
- derivative
- therapeutic drugs
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 239000003601 chymase inhibitor Substances 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical class C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 229940126585 therapeutic drug Drugs 0.000 title 1
- 229940119334 Chymase inhibitor Drugs 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány tárgya hatóanyagként kimázinhibítort tartalmazó gyógyszer,amely mellékhatásoktól mentes, és biztonságosan alkalmazható a bőrvagy egyéb belső szervek fibrózisának megelőzésére vagy kezelésére, ésamely gátolja a betegség kifejlődését, gátolja a szövődményekkifejlődését és javítja a beteg életminőségét. A hatóanyagkimázinhibítor egy (I) általános képletű vegyület, vagy annakgyógyászatilag elfogadható sója, ahol R1, R2, R3 és X küönböző alifásés aromás csoportokat jelent, A jelentése benzolgyűrű. ÓThe subject of the invention is a drug containing a chymase inhibitor as an active ingredient, which is free of side effects and can be safely used to prevent or treat fibrosis of the skin or other internal organs, and which inhibits the development of the disease, prevents the development of complications and improves the patient's quality of life. The active ingredient chymazine inhibitor is a compound of general formula (I) or its pharmaceutically acceptable salt, where R1, R2, R3 and X represent different aliphatic and aromatic groups, A represents a benzene ring. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000050502 | 2000-02-22 | ||
| PCT/JP2001/001321 WO2001062292A1 (en) | 2000-02-22 | 2001-02-22 | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0201284A2 true HUP0201284A2 (en) | 2002-12-28 |
| HUP0201284A3 HUP0201284A3 (en) | 2003-02-28 |
Family
ID=18572274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0201284A HUP0201284A3 (en) | 2000-02-22 | 2001-02-22 | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6500835B2 (en) |
| EP (1) | EP1192949A4 (en) |
| KR (1) | KR20010108519A (en) |
| CN (1) | CN1366461A (en) |
| AU (1) | AU3413401A (en) |
| CA (1) | CA2368366A1 (en) |
| HU (1) | HUP0201284A3 (en) |
| WO (1) | WO2001062292A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1192950B1 (en) | 2000-02-22 | 2006-07-26 | Daiichi Asubio Pharma Co., Ltd. | Therapeutic drugs for dermatitis exhibiting a biphasic skin reaction containing chymase inhibitors as the active ingredient |
| ATE352317T1 (en) | 2000-02-22 | 2007-02-15 | Daiichi Asubio Pharma Co Ltd | THERAPEUTIC TREATMENT OF EOSINOPHILY BY USING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS |
| EP1419785A4 (en) * | 2001-08-24 | 2005-07-06 | Teijin Ltd | Drugs containing chymase inhibitor and ace inhibitor as the active ingredients |
| AU2002367143A1 (en) * | 2001-12-27 | 2003-07-15 | Nippon Kayaku Kabushiki Kaisha | Remedies or preventives for diseases in association with tissue fibrosis |
| JP2003335670A (en) * | 2002-03-15 | 2003-11-25 | Toa Eiyo Ltd | Anti-adhesion agent |
| US20070032466A1 (en) * | 2003-08-22 | 2007-02-08 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
| PL1734970T3 (en) | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Treatment of fibrosis using fxr ligands |
| CN101160290B (en) | 2004-12-02 | 2011-01-19 | 第一三共株式会社 | 7-membered ring compound, its preparation method and pharmaceutical use |
| JP5117382B2 (en) | 2006-05-31 | 2013-01-16 | 第一三共株式会社 | Method for producing 7-membered ring compound |
| TWI532842B (en) | 2009-06-11 | 2016-05-11 | 力博美科股份有限公司 | Aptamer against chymase and use thereof |
| HRP20171873T1 (en) | 2013-02-07 | 2018-02-23 | Scifluor Life Sciences, Inc | Fluorinated integrin antagonists |
| US10842794B2 (en) | 2014-02-07 | 2020-11-24 | Támogatott Kutatócsoportok Irodája | Use of Sigma-1 receptor agonist compounds |
| CN106456578B (en) | 2014-02-07 | 2020-02-18 | 匈牙利科学院大学及其他机构附属研究所 | Use of SIGMA-1 receptor agonist compounds |
| KR102647026B1 (en) | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| KR20170141757A (en) | 2015-04-30 | 2017-12-26 | 사이플루어 라이프 사이언시즈, 인크 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
| WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| EP3338780A1 (en) * | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Use of chymase inhibitors for the treatment of endometriosis, post-operative fibrosis and diseases characterized by the formation of fibrosis |
| JP7072586B2 (en) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | New compounds and uses |
| CA3083760A1 (en) | 2017-11-30 | 2019-06-06 | Ribomic Inc. | Anti-chymase aptamer and use for same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5199279A (en) | 1991-08-13 | 1993-04-06 | Reynolds Martin M | Drum contact freezer system and method |
| CA2137832C (en) | 1992-06-12 | 2000-09-26 | Dennis J. Hoover | Inhibitors of angiotensin i chymase(s) including human heart chymase |
| EP0581738A1 (en) | 1992-07-30 | 1994-02-02 | Ciba-Geigy Ag | Herbizidal pyridylsulfonyl ureas |
| EP0721944B1 (en) | 1994-07-29 | 2001-01-17 | Suntory Limited | Imidazolidine derivative and use thereof |
| JPH08208654A (en) | 1994-11-24 | 1996-08-13 | Wakamoto Pharmaceut Co Ltd | Novel triazine derivative that inhibits chymase activity and suppresses nitric oxide production |
| US5948785A (en) | 1995-04-27 | 1999-09-07 | The Green Cross Corporation | Heterocyclic amide compounds and pharmaceutical use of the same |
| US5596111A (en) | 1995-06-05 | 1997-01-21 | North Dakota State University | Method for preparation of carboxylic acids |
| JP3537231B2 (en) | 1995-07-24 | 2004-06-14 | 第一サントリーファーマ株式会社 | Hydantoin derivatives and uses thereof |
| DE69622148T2 (en) | 1995-09-28 | 2002-10-31 | Suntory Limited, Osaka | CHINAZOZINE DERIVATIVES AND THEIR USE |
| JPH1087567A (en) | 1996-06-05 | 1998-04-07 | Takeda Chem Ind Ltd | Phenol ester derivatives, their production and use |
| JPH107661A (en) | 1996-06-20 | 1998-01-13 | Green Cross Corp:The | Novel heterocyclic amide compounds and their pharmaceutical uses |
| AUPO062696A0 (en) | 1996-06-24 | 1996-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
| JPH1087493A (en) | 1996-09-18 | 1998-04-07 | Shionogi & Co Ltd | Chymase inhibitors containing cephem compounds |
| EP0940400A4 (en) | 1996-10-25 | 2002-10-02 | Mitsubishi Pharma Corp | NOVEL HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USE FOR MEDICINAL PURPOSES |
| JPH10245384A (en) | 1997-03-05 | 1998-09-14 | Teijin Ltd | New triazine sulfone derivative |
| JPH111479A (en) | 1997-06-11 | 1999-01-06 | Nippon Steel Corp | Isoxazole derivatives having an amide bond, and chymase inhibitors and angiotensin II production inhibitors containing them |
| AU744739B2 (en) | 1998-02-17 | 2002-02-28 | Nippon Kayaku Kabushiki Kaisha | Novel acetamide derivative and use thereof |
| JPH11246437A (en) | 1998-03-05 | 1999-09-14 | Yoshitomi Pharmaceut Ind Ltd | Gastrointestinal mucosa protective agent |
| AU4654199A (en) * | 1998-07-23 | 2000-02-14 | Shionogi & Co., Ltd. | Monocyclic beta-lactam compounds and chymase inhibitors containing the same |
| WO2000010982A1 (en) * | 1998-08-21 | 2000-03-02 | Suntory Limited | Quinazoline derivatives and pharmaceutical applications therof |
| WO2001032214A1 (en) | 1999-11-01 | 2001-05-10 | Suntory Limited | Inhibitors against vascular lipid deposition containing chymase-inhibiting substances |
| EP1192950B1 (en) | 2000-02-22 | 2006-07-26 | Daiichi Asubio Pharma Co., Ltd. | Therapeutic drugs for dermatitis exhibiting a biphasic skin reaction containing chymase inhibitors as the active ingredient |
| ATE352317T1 (en) | 2000-02-22 | 2007-02-15 | Daiichi Asubio Pharma Co Ltd | THERAPEUTIC TREATMENT OF EOSINOPHILY BY USING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS |
-
2001
- 2001-02-22 HU HU0201284A patent/HUP0201284A3/en unknown
- 2001-02-22 WO PCT/JP2001/001321 patent/WO2001062292A1/en not_active Ceased
- 2001-02-22 CA CA002368366A patent/CA2368366A1/en not_active Abandoned
- 2001-02-22 EP EP01906224A patent/EP1192949A4/en not_active Withdrawn
- 2001-02-22 AU AU34134/01A patent/AU3413401A/en not_active Abandoned
- 2001-02-22 KR KR1020017013382A patent/KR20010108519A/en not_active Ceased
- 2001-02-22 US US09/959,232 patent/US6500835B2/en not_active Expired - Fee Related
- 2001-02-22 CN CN01800794A patent/CN1366461A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6500835B2 (en) | 2002-12-31 |
| EP1192949A1 (en) | 2002-04-03 |
| CN1366461A (en) | 2002-08-28 |
| AU3413401A (en) | 2001-09-03 |
| EP1192949A4 (en) | 2005-11-09 |
| HUP0201284A3 (en) | 2003-02-28 |
| US20020183338A1 (en) | 2002-12-05 |
| CA2368366A1 (en) | 2001-08-30 |
| KR20010108519A (en) | 2001-12-07 |
| WO2001062292A1 (en) | 2001-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0201284A2 (en) | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient | |
| ES2295609T3 (en) | TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN. | |
| LU90956I2 (en) | Metvix active ingredient methylaminolevulinic in the form of a salt preferably methylaminolevulinic hydrochloride | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| FI943948A0 (en) | Heterocyclic carbonic acid derivatives | |
| NO20065638L (en) | Controlled-release formulations containing vardenafil | |
| YU24503A (en) | New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | |
| NO20051263L (en) | New use of benzothiazole derivatives | |
| DE59401401D1 (en) | PHARMACEUTICAL FORMULA FOR TREATING NICOTINE DEPENDENCY | |
| SE9901573D0 (en) | New compounds | |
| HUP0402577A2 (en) | Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them | |
| HUP0104963A2 (en) | Compositions for the treatment of skin diseases | |
| DE60035429D1 (en) | USE OF SULFODE HYDROABETIC ACIDS FOR THE TREATMENT OF INFLAMMATORY ENDURANCE | |
| HUP0201282A2 (en) | Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient | |
| SE0201837D0 (en) | Chemical compounds | |
| SE9901572D0 (en) | New compounds | |
| EP1695969A4 (en) | ALPHA-AMINO ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS | |
| IL112695A0 (en) | Pyridazinone derivatives and pharmaceutical compositions containing the same | |
| HUP0401798A2 (en) | Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states | |
| MY122570A (en) | Benzamide derivatives and drugs containing the same | |
| SE9900190D0 (en) | New compounds | |
| NO950177L (en) | Pharmacologically active derivatives | |
| NO975790L (en) | Use of allylamine derivatives, such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection-associated diseases | |
| ATE447953T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR TREATING LEISHMANIASIS | |
| SE0103272D0 (en) | Chemical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |